Company intelligence / Profile preview

Nucleic Bio

South San Francisco, California, USAnucleic.bio ↗

Ownership: Private
Development stage: Other

Overview

Nucleic is a biotechnology company dedicated to the discovery of small molecule medicines that target RNA. The company utilizes a proprietary platform to map and exploit the structural complexity of RNA, enabling the development of therapies for previously undruggable targets. By combining high-throughput experimental data with computational insights, Nucleic identifies novel binding pockets within RNA molecules. Their initial focus includes therapeutic programs in oncology, rare diseases, and immunology. Headquartered in South San Francisco, the company is supported by a syndicate of top-tier venture capital firms.

Therapeutic areas: Rare DiseasesImmunologyOncology
Modalities: Small moleculeRNA-targeting small molecule
Industry: Biotech

Beyond the preview

Go deeper on Nucleic Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nucleic Bio.

Explore the full profile